Mucoadhesive Polymers Enhance Ocular Drug Delivery: Proof of Concept Study with 0.5% Tropicamide in Dogs

2021 ◽  
Author(s):  
Dikla Arad ◽  
Shachar Komoron ◽  
Oren Pe'er ◽  
Lionel Sebbag ◽  
Ron Ofri
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Proof Of Concept ◽  
Concept Study ◽  
Mucoadhesive Polymers

scholarly journals Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies

2020 ◽  
Vol Volume 14 ◽  
pp. 139-147
Author(s):  
Hugo Quiroz-Mercado ◽  
Ehud Ivri ◽  
Roberto Gonzalez-Salinas ◽  
Iraklis C Kourtis ◽  
Joseph Gilbert ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Clinical Evaluation ◽  
Phase 1 ◽  
Ocular Drug Delivery ◽  
Proof Of Concept ◽  
Two Phase

scholarly journals A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study

2019 ◽  
Vol 167 ◽  
pp. 83-88 ◽  
Author(s):  
Subhra Mandal ◽  
Pavan Kumar Prathipati ◽  
Michael Belshan ◽  
Christopher J. Destache
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Proof Of Concept ◽  
Concept Study ◽  
Nano Drug Delivery ◽  
Long Acting ◽  
Hiv 1

Results of first-in-man proof of concept study of ultrasound-triggered drug delivery in liver tumours

2019 ◽  
Vol 74 ◽  
pp. e20
Author(s):  
Paul C. Lyon ◽  
Michael Gray ◽  
Christophoros Mannaris ◽  
Lisa Folkes ◽  
Michael Stratford ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Proof Of Concept ◽  
Liver Tumours ◽  
Concept Study

Mucoadhesive Polymers for Enhancing Retention in Ocular Drug Delivery: A Critical Review

2014 ◽  
Vol 2 (4) ◽  
pp. 467-502 ◽  
Author(s):  
Anubha Khare ◽  
Kanchan Grover ◽  
Pravin Pawar ◽  
Inderbir Singh
Keyword(s):  
Drug Delivery ◽  
Critical Review ◽  
Ocular Drug Delivery ◽  
Mucoadhesive Polymers

scholarly journals Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats

2021 ◽  
Vol 8 ◽  
Author(s):  
Michael Klotsman ◽  
Christopher A. Adin ◽  
Wayne H. Anderson ◽  
Chen Gilor
Keyword(s):  
Drug Delivery ◽  
Weight Loss ◽  
Drug Delivery System ◽  
Delivery System ◽  
Plasma Concentrations ◽  
Investigational Drug ◽  
Proof Of Concept ◽  
Minimal Impact ◽  
Concept Study

Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that plays an important role in glucose homeostasis and food intake. In people, GLP-1 receptor agonists (GLP-1RAs) are commonly used for the treatment of type 2 diabetes mellitus (DM) and obesity; however, non-adherence to injectable medications is common. OKV-119 is an investigational drug delivery system intended for subdermal implantation and delivery of the GLP-1RA exenatide for up to 6 months.Hypothesis/Objectives: Develop protocols for the subcutaneous (SC) insertion and removal of OKV-119 and to evaluate its tolerability, in vivo drug-releasing characteristics, and weight-loss effects in cats.Animals: Two cadaveric and 19 purpose-bred cats.Methods: In cadavers, OKV-119 insertion protocol and imaging were performed at three SC locations. The safety and tolerability of OKV-119 implants were assessed in a small (n = 4 cats) 62-day study. Weekly plasma exenatide concentrations and body weight were measured in a 42-day proof-of-concept study designed to evaluate OKV-119 prototypes implanted in cats (n = 15).Results: In anesthetized cats, the duration of insertion and removal procedures was 1–2 min. OKV-119 was easily identified on radiographs, and well-tolerated without any apparent implant site reactions. Following implantation, exanatide plasma concentrations were observed for up to 35 days. Plasma exenatide concentrations were correlated to weight loss.Conclusion and clinical importance: Our findings suggest that OKV-119 could be easily inserted and removed during a routine clinic visit and can be used to safely and effectively deliver exenatide. Future studies of OKV-119, configured to release exenatide for a longer extended months-long duration, are warranted to determine whether the combination of metabolic improvements and beneficial weight-loss, coupled with minimal impact on pet-owner's lifestyle, lead to improved outcomes for obese cats and feline DM patients.

The use of mucoadhesive polymers in ocular drug delivery

2005 ◽  
Vol 57 (11) ◽  
pp. 1595-1639 ◽  
Author(s):  
A LUDWIG
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Mucoadhesive Polymers

scholarly journals Current Approaches to Use Cyclodextrins and Mucoadhesive Polymers in Ocular Drug Delivery—A Mini-Review

2019 ◽  
Vol 87 (3) ◽  
pp. 15 ◽  
Author(s):  
Bíró ◽  
Aigner
Keyword(s):  
Drug Delivery ◽  
Retention Time ◽  
Short Review ◽  
Theoretical Background ◽  
Ocular Drug Delivery ◽  
Therapeutic Effects ◽  
Cyclodextrin Derivatives ◽  
Anatomical Structures ◽  
Mucoadhesive Polymers ◽  
Defensive Mechanisms

Ocular drug delivery provides a challenging opportunity to develop optimal formulations with proper therapeutic effects and acceptable patient compliance because there are many restricting factors involved, such as complex anatomical structures, defensive mechanisms, rapid drainage, and applicability issues. Fortunately, recent advances in the field mean that these problems can be overcome through the formulation of innovative ophthalmic products. Through the addition of solubility enhancer cyclodextrin derivatives and mucoadhesive polymers, the permeability of active ingredients is improved, and retention time is increased in the ocular surface. Therefore, preferable efficacy and bioavailability can be achieved. In this short review, the authors describe the theoretical background, technological possibilities, and the current approaches in the field of ophthalmology.

Mucoadhesive Polymers for Enhancing Retention in Ocular Drug Delivery

2015 ◽  
pp. 451-484 ◽  
Author(s):  
Anubha Khare ◽  
Kanchan Grover ◽  
Pravin Pawar ◽  
Inderbir Singh
Keyword(s):  
Drug Delivery ◽  
Ocular Drug Delivery ◽  
Mucoadhesive Polymers
Sign in / Sign up

Export Citation Format

Share Document